Cadherin-16 (CDH16) immunohistochemistry: a useful diagnostic tool for renal cell carcinoma and papillary carcinomas of the thyroid
Standard
Cadherin-16 (CDH16) immunohistochemistry: a useful diagnostic tool for renal cell carcinoma and papillary carcinomas of the thyroid. / Lennartz, Maximilian; Csomós, Henrietta; Chirico, Viktoria; Weidemann, Sören; Gorbokon, Natalia; Menz, Anne; Büscheck, Franziska; Hube-Magg, Claudia; Höflmayer, Doris; Bernreuther, Christian; Blessin, Niclas C; Lebok, Patrick; Sauter, Guido; Steurer, Stefan; Burandt, Eike; Dum, David; Krech, Till; Simon, Ronald; Minner, Sarah; Jacobsen, Frank; Clauditz, Till S; Luebke, Andreas M; Siraj, Abdul Khalid; Al-Dayel, Fouad; Al-Kuraya, Khawla S; Hinsch, Andrea.
In: SCI REP-UK, Vol. 13, No. 1, 09.08.2023, p. 12917.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cadherin-16 (CDH16) immunohistochemistry: a useful diagnostic tool for renal cell carcinoma and papillary carcinomas of the thyroid
AU - Lennartz, Maximilian
AU - Csomós, Henrietta
AU - Chirico, Viktoria
AU - Weidemann, Sören
AU - Gorbokon, Natalia
AU - Menz, Anne
AU - Büscheck, Franziska
AU - Hube-Magg, Claudia
AU - Höflmayer, Doris
AU - Bernreuther, Christian
AU - Blessin, Niclas C
AU - Lebok, Patrick
AU - Sauter, Guido
AU - Steurer, Stefan
AU - Burandt, Eike
AU - Dum, David
AU - Krech, Till
AU - Simon, Ronald
AU - Minner, Sarah
AU - Jacobsen, Frank
AU - Clauditz, Till S
AU - Luebke, Andreas M
AU - Siraj, Abdul Khalid
AU - Al-Dayel, Fouad
AU - Al-Kuraya, Khawla S
AU - Hinsch, Andrea
N1 - © 2023. Springer Nature Limited.
PY - 2023/8/9
Y1 - 2023/8/9
N2 - Cadherin-16 (CDH16) plays a role in the embryonal development in kidney and thyroid. Downregulation of CDH16 RNA was found in papillary carcinomas of the thyroid. To determine the expression of CDH16 in tumors and to assess the diagnostic utility a tissue microarray containing 15,584 samples from 152 different tumor types as well as 608 samples of 76 different normal tissue types was analyzed. A membranous CDH16 immunostaining was predominantly seen in thyroid, kidney, cauda epididymis, and mesonephric remnants. In the thyroid, CDH16 staining was seen in 100% of normal samples, 86% of follicular adenomas, 60% of follicular carcinomas, but only 7% of papillary carcinomas (p < 0.0001). CDH16 positivity was frequent in nephrogenic adenomas (100%), oncocytomas (98%), chromophobe (97%), clear cell (85%), and papillary (76%) renal cell carcinomas (RCCs), various subtypes of carcinoma of the ovary (16-56%), various subtyped of carcinomas of the uterus (18-40%), as well as in various subtypes of neuroendocrine neoplasms (4-26%). Nineteen further tumor entities showed a weak to moderate CDH16 staining in up to 8% of cases. Our data suggest CDH16 as a potential diagnostic marker-as a part of a panel-for the identification of papillary carcinomas of the thyroid, nephrogenic adenomas, and the distinction of renal cell tumors from other neoplasms.
AB - Cadherin-16 (CDH16) plays a role in the embryonal development in kidney and thyroid. Downregulation of CDH16 RNA was found in papillary carcinomas of the thyroid. To determine the expression of CDH16 in tumors and to assess the diagnostic utility a tissue microarray containing 15,584 samples from 152 different tumor types as well as 608 samples of 76 different normal tissue types was analyzed. A membranous CDH16 immunostaining was predominantly seen in thyroid, kidney, cauda epididymis, and mesonephric remnants. In the thyroid, CDH16 staining was seen in 100% of normal samples, 86% of follicular adenomas, 60% of follicular carcinomas, but only 7% of papillary carcinomas (p < 0.0001). CDH16 positivity was frequent in nephrogenic adenomas (100%), oncocytomas (98%), chromophobe (97%), clear cell (85%), and papillary (76%) renal cell carcinomas (RCCs), various subtypes of carcinoma of the ovary (16-56%), various subtyped of carcinomas of the uterus (18-40%), as well as in various subtypes of neuroendocrine neoplasms (4-26%). Nineteen further tumor entities showed a weak to moderate CDH16 staining in up to 8% of cases. Our data suggest CDH16 as a potential diagnostic marker-as a part of a panel-for the identification of papillary carcinomas of the thyroid, nephrogenic adenomas, and the distinction of renal cell tumors from other neoplasms.
KW - Male
KW - Female
KW - Humans
KW - Carcinoma, Renal Cell/genetics
KW - Immunohistochemistry
KW - Thyroid Gland/pathology
KW - Carcinoma, Papillary/diagnosis
KW - Kidney Neoplasms/pathology
KW - Carcinoma
KW - Cadherins/metabolism
KW - Biomarkers, Tumor/metabolism
KW - Thyroid Neoplasms/diagnosis
U2 - 10.1038/s41598-023-39945-2
DO - 10.1038/s41598-023-39945-2
M3 - SCORING: Journal article
C2 - 37558687
VL - 13
SP - 12917
JO - SCI REP-UK
JF - SCI REP-UK
SN - 2045-2322
IS - 1
ER -
